# A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05970497/  
OnCo record `nct05970497` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Relatlimab + nivolumab, Pembrolizumab in melanoma, run by Krystal Biotech, Inc., now recruiting.

## Summary

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05970497 by Krystal Biotech, Inc., with 240 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-07. Interventions recorded: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab). Conditions listed: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05970497
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies
- Sponsor: Krystal Biotech, Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT05970497: https://clinicaltrials.gov/study/NCT05970497

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/)
- companies: [Krystal Biotech](https://onco.cc/companies/krystal-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05970497.json